Becton, Dickinson & Co. is a global medical technology company, which engages in the development, manufacture, and sale of medical supplies, devices, laboratory equipment, and diagnostic products. The company is headquartered in Franklin Lakes, New Jersey and currently employs 72,000 full-time employees. The firm is engaged in the development, manufacture and sale of a broad range of medical supplies, devices, laboratory equipment and diagnostic products used by healthcare institutions, physicians, life science researchers, clinical laboratories, and more. The company operates through five segments: BD Medical Essentials, BD Connected Care, BD BioPharma Systems, BD Interventional, and BD Life Sciences. BD Medical Essentials segment includes medication delivery solutions and specimen management. BD Connected Care segment includes medication management solutions and advanced patient monitoring. BD Interventional segment includes urology and critical care, peripheral intervention and surgery. Its Life Sciences segment includes diagnostic solutions and biosciences.
Leveraging in-depth analyst evaluations, we have synthesized key insights from expert assessments to present a positive outlook for BDX. Analysts highlight solid fundamentals and favorable market sentiment, suggesting upside potential in the near term. Based on this thorough expert analysis, we maintain an optimistic view of this stock. Our conclusion: BDX is a Buy candidate.
BDX stock price ended at $144.18 on 星期三, after dropping 2.26%
On the latest trading day May 13, 2026, the stock price of BDX fell by 2.26%, dropping from $146.59 to $144.18. During the session, the stock saw a volatility of 2.63%, with prices oscillating between a daily low of $142.83 and a high of $146.59. On the latest trading day, the trading volume for BDX rose by 364.8K shares, despite the declining prices. This uptick in volume may signal heightened risk in the near term. In total, 3.8M shares were traded, with a market value of approximately $39.7B.